

**Supplementary Table S6. Summary of planned and ongoing clinical trials for proposed biosimilars of bevacizumab, rituximab, and trastuzumab in oncology**

	Biosimilar (alternative name[s]; company)	Phase (studies)	Interventions	Disease	Outcome measures	Enrollment N	Start or end date	Status
<b>Bevacizumab</b>	ABP 215 (Amgen/Allergan)	Comparative efficacy/safety (1) [1]	ABP 215 or beva	Metastatic non- small-cell lung cancer	Efficacy, safety	642	Oct 2013/ Sep 2015	ANR
	BCD-021 (Biocad)	Comparative efficacy/safety (1) [2]	BCD-021 or beva	Non-small-cell lung cancer	Efficacy, safety	214	Oct 2012/ Nov 2015	ANR
	BEVZ92 (mAbxience/ Laboratorio Elea/LIBBS)	PK/safety (1) [3]	BEVZ92 or beva	Metastatic colorectal cancer	PK, efficacy, safety, ADA <sub>b</sub>	100	Oct 2014/ Sep 2016	R
	PF-06439535 (Pfizer)	PK/safety (1) [4]	PF-06439535 or beva	Healthy	PK parameters	102	Jan 2014/ Aug 2014	C
		Comparative efficacy/safety (1) [5]	PF-06439535 or beva-EU	Non-small-cell lung cancer	Efficacy	710	Apr 2015/ Jan 2018	R
SB8 (Samsung Bioepis)	PK/safety (1) [6]	SB8 or beva	Healthy	PK, safety, ADA <sub>b</sub>	114	May 2015/ NP	NYR	
<b>Rituximab</b>	BCD-020 (Biocad)	Comparative efficacy/safety (1) [7]	BCD-020 or MabThera (ritux-EU)	Follicular non- Hodgkin lymphoma or nodal marginal zone lymphoma or splenic marginal zone lymphoma	Efficacy, safety	134	Sep 2011/ Dec 2015	R
	CT-P10 (Celltrion)	Comparative efficacy/safety (2) [8, 9]	CT-P10 or Rituxan (ritux)	Follicular lymphoma	PK, efficacy	250	Jun 2014/ Jun 2020	R
			CT-P10 or Rituxan (ritux)	Follicular lymphoma	Efficacy, safety	104	Oct 2015/ Aug 2020	NYR
	GP2013 (Sandoz/ Novartis)	Comparative efficacy/safety (1) [10]	GP2013/Ritux	Follicular lymphoma	Efficacy, safety	618	Dec 2011/ Mar 2018	ANR
	PF-05280586 (Pfizer)	Comparative efficacy/safety (1) [11]	PF-05280586 or MabThera (ritux-EU)	Follicular lymphoma	Efficacy, safety	394	Sep 2014/ May 2017	R
RTXM83 (mAbxience/ Laboratorio Elea/LIBBS)	Comparative efficacy/safety (1) [12]	RTXM83 + CHOP or ritux + CHOP	Diffuse large B-cell lymphoma	Efficacy, safety, PK, PD, immunogenicity	250	May 2013/ NP	R	
<b>Trastuzumab</b>	ABP 980 (Amgen/Allergan)	Comparative efficacy/safety (1) [13]	ABP 980/tras/ epirubicin/ cyclophosphamide/ paclitaxel	Breast cancer	Efficacy, safety	808	Apr 2014/ Feb 2017	R
	BCD-022 (Biocad)	Comparative efficacy/safety (1) [14]	BCD-022/tras/ paclitaxel	HER2 <sup>+</sup> metastatic breast cancer	Efficacy, safety, PK	206	Oct 2012/ Mar 2015	ANR
	CT-P6 (Celltrion)	Comparative efficacy/safety (2) [15, 16]	CT-P6/Herceptin (tras)/paclitaxel	Metastatic breast cancer	Efficacy, safety	383	Jun 2010/ Dec 2017	ANR
			CT-P6/Herceptin (tras)	HER2 <sup>+</sup> breast cancer	Efficacy, safety	532	June 2014/ June 2019	R
	PF-05280014 (Pfizer)	PK/safety (1) [17]	PF-05280014/ Herceptin (tras)	Healthy	Safety	162	Jan 2014/ Feb 2014	C
		Clinical (1) [18] <sup>a</sup>	PF-05280014/ Taxotere/Paraplatin/ tras-EU/Taxotere/ Paraplatin	Early-stage breast cancer	PK, efficacy, Safety, immunogenicity	220	Sept 2014/ Dec 2016	R
		Comparative efficacy/safety (1) [19] <sup>a</sup>	PF-05280014/ paclitaxel/Herceptin (tras)/paclitaxel	Metastatic breast cancer	Efficacy, safety, immunogenicity, PK	690	Mar 18/ Sep 2015	R
SB3 (Samsung Bioepis)	PK/safety (1) [20]	SB3/Herceptin (tras)	Healthy	PK, safety	109	Feb 2014/ May 2014	C	
	Comparative efficacy/safety (1) [21]	SB3/Herceptin (tras- EU)/Herceptin (tras- US)	HER2 <sup>+</sup> early or locally advanced breast cancer	Efficacy	806	Apr 2014/ May 2016	R	

ADA<sub>b</sub> antidrug antibody, ANR Active not yet recruiting, beva bevacizumab, C Completed, CHOP cyclophosphamide, doxorubicin, vincristine, prednisolone, HER2 human epidermal growth factor receptor 2, NP not provided, NYR not yet recruiting, PD pharmacodynamics, PK pharmacokinetics, R recruiting, ritux rituximab, tras trastuzumab

<sup>a</sup> Studies with published protocols (see Table 3 in the print edition).

References (next page)

1. ClinicalTrials.gov. Efficacy and safety study of ABP 215 compared with bevacizumab in subjects with advanced non-small cell lung cancer. National Institutes of Health, US National Library of Medicine, Bethesda, MD. 2013 (last update 28 April 2016). <https://clinicaltrials.gov/show/NCT01966003>. Accessed 21 June 2016. 2. ClinicalTrials.gov. A safety and efficacy study of BCD-021 with paclitaxel and carboplatin compared to Avastin with paclitaxel and carboplatin in non-small cell lung cancer. National Institutes of Health, US National Library of Medicine, Bethesda, MD. 2012 (last update 2 Feb 2015). <https://clinicaltrials.gov/show/NCT01763645>. Accessed 21 June 2016. 3. ClinicalTrials.gov. Bioequivalence study bevacizumab biosimilar (BEVZ92) versus bevacizumab (Avastin®) in first-line treatment mCRC patients. National Institutes of Health, US National Library of Medicine, Bethesda, MD. 2014 (last update 19 May 2016). <https://clinicaltrials.gov/show/NCT02069704>. Accessed 21 June 2016. 4. ClinicalTrials.gov. A pharmacokinetic study comparing PF-06439535 and bevacizumab in healthy male volunteers (REFLECTIONS B739-01). National Institutes of Health, US National Library of Medicine, Bethesda, MD. 2014 (last update 14 Aug 2014). <https://clinicaltrials.gov/show/NCT02031991>. Accessed 21 June 2016. 5. ClinicalTrials.gov. A comparative study of PF-06439535 plus paclitaxel-carboplatin and bevacizumab plus paclitaxel-carboplatin patients with advanced non-squamous NSCLC. National Institutes of Health, US National Library of Medicine, Bethesda, MD. 2015 (last update 12 Aug 2015). <https://clinicaltrials.gov/show/NCT02364999>. Accessed 21 June 2016. 6. ClinicalTrials.gov. Pharmacokinetic, safety, tolerability, and immunogenicity study of SB8 in healthy male subjects. National Institutes of Health, US National Library of Medicine, Bethesda, MD. 2015 (last update 24 Nov 2015). <https://clinicaltrials.gov/show/NCT02453672>. Accessed 21 June 2016. 7. Jacobs I, et al. Monoclonal antibody and fusion protein biosimilars across therapeutic areas: a systematic review of published evidence. *BioDrugs*. 2016; in press. 8. ClinicalTrials.gov. To demonstrate equivalence of pharmacokinetics and noninferiority of efficacy for CT-P10 in comparison with Rituxan (rituximab). National Institutes of Health, US National Library of Medicine, Bethesda, MD. 2014 (last update 11 Feb 2016). <https://clinicaltrials.gov/show/NCT02162771>. Accessed 21 June 2016. 9. ClinicalTrials.gov. To compare efficacy and safety between CT-P10 and Rituxan in patients with low tumour burden follicular lymphoma. National Institutes of Health, US National Library of Medicine, Bethesda, MD. 2014 (last update 25 April 2016). <https://clinicaltrials.gov/show/NCT02260804>. Accessed 21 June 2016. 10. ClinicalTrials.gov. GP2013 in the treatment of patients with previously untreated, advanced stage follicular lymphoma (ASSIST\_FL). National Institutes of Health, US National Library of Medicine, Bethesda, MD. 2011 (last update 15 March 2016). <https://clinicaltrials.gov/show/NCT01419665>. Accessed 21 June 2016. 11. ClinicalTrials.gov. A study of PF-05280586 (rituximab-Pfizer) or MabThera® (rituximab-EU) for the first-line treatment of patients with CD20-positive, low tumor burden, follicular lymphoma (REFLECTIONS B328-06). National Institutes of Health, US National Library of Medicine, Bethesda, MD. 2014 (last update 5 July 2016). <https://clinicaltrials.gov/show/NCT02213263>. Accessed 21 June 2016. 12. ClinicalTrials.gov. Study of RTX83 plus CHOP chemotherapy versus a rituximab plus CHOP therapy in patients with non Hodgkin's lymphoma. National Institutes of Health, US National Library of Medicine, Bethesda, MD. 2014 (last update 19 May 2016). <https://clinicaltrials.gov/show/NCT02268045>. Accessed 21 June 2016. 13. ClinicalTrials.gov. Efficacy and safety study of ABP 980 compared with trastuzumab in subjects with HER2 positive early breast cancer (Lilac). National Institutes of Health, US National Library of Medicine, Bethesda, MD. 2013 (last update 11 May 2016). <https://clinicaltrials.gov/show/NCT01901146>. Accessed 21 June 2016. 14. ClinicalTrials.gov. A safety and efficacy study of BCD-022 with paclitaxel compared to Herceptin with paclitaxel in HER2-positive metastatic breast cancer patients. National Institutes of Health, US National Library of Medicine, Bethesda, MD. 2013 (last update 2 Feb 2015). <https://clinicaltrials.gov/show/NCT01764022>. Accessed 21 June 2016. 15. ClinicalTrials.gov. Demonstrate efficacy and safety of metastatic breast cancer (Compare). National Institutes of Health, US National Library of Medicine, Bethesda, MD. 2010 (last update 11 Feb 2015). <https://clinicaltrials.gov/show/NCT01084876>. Accessed 21 June 2016. 16. ClinicalTrials.gov. Efficacy and safety evaluating study of CT-P6 in HER2 positive early breast cancer. National Institutes of Health, US National Library of Medicine, Bethesda, MD. 2014 (last update 17 Dec 2015). <https://clinicaltrials.gov/show/NCT02162667>. Accessed 21 June 2016. 17. ClinicalTrials.gov. A study evaluating the safety of PF-05280014 and trastuzumab in healthy male volunteers (REFLECTIONS B327-06). National Institutes of Health, US National Library of Medicine, Bethesda, MD. 2013 (last update 21 April 2014). <https://clinicaltrials.gov/show/NCT02015156>. Accessed 21 June 2016. 18. Jacobs I, et al. A phase 3 randomized, double-blind trial comparing PF-05280014 + docetaxel and carboplatin vs. trastuzumab + docetaxel and carboplatin for neoadjuvant treatment of operable HER2+ breast cancer. *Cancer Res*. 2015;75(9 suppl):Abstr OT3-1-02. 19. Ewesuedo R, et al. A phase 3 randomized, double-blind trial comparing PF-05280014 + paclitaxel vs. trastuzumab + paclitaxel for treatment of HER2+ metastatic breast cancer. *Cancer Res* 2013;73. 20. ClinicalTrials.gov. Pharmacokinetic, safety, tolerability and immunogenicity study of SB3 in healthy male subjects. National Institutes of Health, US National Library of Medicine, Bethesda, MD. 2014 (last update 19 May 2014). <https://clinicaltrials.gov/show/NCT02075073>. Accessed 21 June 2016. 21. ClinicalTrials.gov. A study to compare the effect of SB3 and Herceptin® in women with HER2 positive breast cancer. National Institutes of Health, US National Library of Medicine, Bethesda, MD. 2014 (last update 2 May 2016). <https://clinicaltrials.gov/show/NCT02149524>. Accessed 21 June 2016.

